Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon OrganicsROMJF +0.46%50 3-Year EBITDA Growth Rate is 166.80% as of Mar. 2026, which is 373% above its 10-year median of 35.30. GuruFocus rates ROMJF with a GF Score™ of 50/100 and a GF Value™ of $0.39 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 814 Drug Manufacturers companies, Rubicon Organics ranks better than 99.39% on this metric.
During the past 12 months, Rubicon Organics's average EBITDA Per Share Growth Rate was -16.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 166.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rubicon Organics was 166.80% per year. The lowest was -16.30% per year. And the median was 35.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Rubicon Organics 3-Year EBITDA Growth Rate Related Terms
ROMJF vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rubicon Organics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Organics 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Organics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rubicon Organics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 166.80% mean?
Rubicon Organics (ROMJF) has a 3-Year EBITDA Growth Rate of 166.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rubicon Organics and its competitors. This is 373% above median its historical median of 35.30. According to the industry distribution chart, Rubicon Organics ranks #5 out of 814 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Rubicon Organics' 3-Year EBITDA Growth Rate too high?
Rubicon Organics' current 3-Year EBITDA Growth Rate of 166.80% is 373% above median its 10-year median of 35.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Rubicon Organics' value of 166.80% is 1774.2% above this industry median. Based on the distribution chart, Rubicon Organics ranks #5 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rubicon Organics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rubicon Organics' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rubicon Organics ranks #5 out of 814 companies for 3-Year EBITDA Growth Rate. This places Rubicon Organics in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Rubicon Organics' value of 166.80% is 1774.2% above this benchmark. While the company's 10-year median is 35.30 vs. the industry median of 8.90, Rubicon Organics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Organics's current 3-Year EBITDA Growth Rate of 166.80% is 1774.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rubicon Organics and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Organics's current 3-Year EBITDA Growth Rate is 166.80%, which is 373% above median its own 10-year median of 35.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Organics stock overvalued right now?
Based on GuruFocus' analysis, Rubicon Organics (ROMJF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.39, compared to a current price of $0.33 — trading 16.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 166.80%, which is 373% above median its 10-year median of 35.30 and 1774.2% above the Drug Manufacturers industry median of 8.90. Rubicon Organics' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rubicon Organics (ROMJF), the current 3-Year EBITDA Growth Rate is 166.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rubicon Organics (ROMJF) Overvalued in 2026?
Based on GuruFocus' analysis, Rubicon Organics stock appears to be undervalued.
The current stock price of $0.33 is trading 16.3% below its estimated GF Value™ of $0.39.
GuruFocus considers Rubicon Organics to be Modestly Undervalued.
Key valuation signals for ROMJF:
3-Year EBITDA Growth Rate: 166.80% (373% above median its 10-year median of 35.30)
GF Value™: $0.39 vs. price of $0.33 (16.3% below fair value)
Industry Position: 1774.2% above the Drug Manufacturers median (#5 of 814)
No single metric tells the full story. See the ROMJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rubicon Organics Inc is engaged in the production and sale of cannabis in Canada. The company produces and processes organic cannabis at its wholly owned, federally licensed 125,000 square foot facility in Delta, British Columbia which it sells under its wholly owned brands and certain wholesale channels. Its brands include Simply Bare, 1964 Supply Co, Wildflower, and Homestead Cannabis Supply. It operates in a single reportable segment, being the production and sale of cannabis in Canada.
50GF Score
Get the complete analysis for ROMJF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROMJF has been successfully added to your 
